Company News

Oxford Vacmedix and CHAIN Biotech collaborate to develop oral vaccines

Oxford Vacmedix and CHAIN Biotech have signed Heads of Terms for a Collaboration Agreement to develop and commercialise oral vaccines targeting cancer & infectious disease Oxford, UK – 4th January 2020 – FOR IMMEDIATE RELEASE Press Release – OVM CHAIN Collaboration Oxford 4th Jan 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on […]

Oxford Vacmedix and CHAIN Biotech collaborate to develop oral vaccines Read More »

Oxford Vacmedix announces filing of new patent for Covid-19 vaccine and diagnostics

New patent using Recombinant Overlapping Peptide (ROP technology) as novel approach to SARS-Cov-2 pandemic filed, after rapid development and initial testing Oxford, UK – 24th November 2020 – FOR IMMEDIATE RELEASE Press Release-Patent filed for Covid-19 vaccine and diagnostics 24-11-20 Oxford 24th November 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on the

Oxford Vacmedix announces filing of new patent for Covid-19 vaccine and diagnostics Read More »

Oxford Vacmedix founder Dr Shisong Jiang appointed as Senior Industrial Fellow at University of Oxford

Shisong Jiang is appointed to the newly created role of Senior Industrial Fellow in the Department of Oncology at the University of Oxford Oxford, UK – 9th November 2020 – FOR IMMEDIATE RELEASE Download PDF – Press Release-Senior Industrial Fellow 09-11-20 Oxford 9th November 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on

Oxford Vacmedix founder Dr Shisong Jiang appointed as Senior Industrial Fellow at University of Oxford Read More »

Oxford Vacmedix announces collaboration to develop vaccine and diagnostic tests for Covid-19

Collaboration with the Nuffield Department of Medicine, University of Oxford will use recombinant overlapping peptide technology to develop a novel vaccine and diagnostic tests for Covid-19 Press Release Covid-19 project 12 May 2020 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today that it will use

Oxford Vacmedix announces collaboration to develop vaccine and diagnostic tests for Covid-19 Read More »

Cancer vaccine firm Oxford Vacmedix appoints leading global CRO to run Phase 1 trial of OVM-200

Oxford Vacmedix appoints a Global Contract Research Organisation (CRO) to run a Phase 1 trial of immunotherapy cancer vaccine OVM-200 in the UK. Oxford, UK – 24th January 2020 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that a leading global CRO has been appointed

Cancer vaccine firm Oxford Vacmedix appoints leading global CRO to run Phase 1 trial of OVM-200 Read More »

Cancer vaccine firm Oxford Vacmedix announces Innovate UK grant for novel application of ROP technology

Grant will fund joint research by Imperial College, London and Oxford Vacmedix into antimicrobial resistance, in collaboration with the Ditan Hospital in Beijing, China Oxford, UK – 19th December 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today the award of an Innovate UK grant

Cancer vaccine firm Oxford Vacmedix announces Innovate UK grant for novel application of ROP technology Read More »

Cancer vaccine firm Oxford Vacmedix appoints Eurofins CDMO as Contract Development & Manufacturing Organisation

Oxford Vacmedix appoints Belgium based Eurofins CDMO to carry out the GMP manufacturing of the lead immunotherapy cancer vaccine OVM-200, to support Phase 1 application. Oxford, UK – 22nd November 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that Eurofins CDMO based in Belgium

Cancer vaccine firm Oxford Vacmedix appoints Eurofins CDMO as Contract Development & Manufacturing Organisation Read More »

Oxford Vacmedix announces Research Collaboration with University of Oxford

Grant to fund research into novel applications and development of new cancer vaccines using the recombinant overlapping peptide technology developed by Dr. Shisong Jiang. Oxford, UK – 9th July 2019 Oxford Vacmedix (OVM), the UK based biopharma company, focused on the development of a new generation of cancer vaccines, announced today that research into its

Oxford Vacmedix announces Research Collaboration with University of Oxford Read More »

Cancer vaccine firm Oxford Vacmedix announces collaboration and Innovate UK grant

CHAIN Biotechnology and University of Oxford have been awarded grant funding to develop live biotherapeutics that support oral delivery of Oxford Vacmedix’s immunotherapy cancer vaccines. Oxford, UK – 2nd July 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the award of an Innovate UK

Cancer vaccine firm Oxford Vacmedix announces collaboration and Innovate UK grant Read More »

Cancer vaccine firm Oxford Vacmedix appoints Xpress Biologics as Contract Manufacturing Organisation

Oxford Vacmedix appoints Belgium based Xpress Biologics to carry out the GLP manufacturing of both lead immunotherapy cancer vaccines, to support Phase 1 applications. Oxford, UK – 8th February 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that Xpress Biologics based in Belgium has

Cancer vaccine firm Oxford Vacmedix appoints Xpress Biologics as Contract Manufacturing Organisation Read More »